Skip to main content
. 2022 Aug 23;37(1):2265–2282. doi: 10.1080/14756366.2022.2104841

Table 7.

Inhibitory activity of thiazolyl-pyrazoline derivatives 10 b and 10d against EGFR-mutated NSCLC cell lines.

Compound IC50 (µM)
NCI-H1650 NCI-H1975
10b 5.7 ± 0.5 6.2 ± 0.9
10d 3.5 ± 0.2 4.4 ± 0.6
Gefitinib >20 >20